ERIC SANDQUIST

215-***-**** adrdmi@r.postjobfree.com https://www.linkedin.com/in/eric-sandquist-4b96963/

Profile

Biopharmaceutical leader who enables teams to achieve and surpass sales and profit objectives in large and medium domestic and international companies. Using a structured approach, leads teams to tackle complex business problems, identify performance gaps, and develop and implement innovative and profitable solutions. Deep expertise in patient and thought leader engagement and clinical trials.

Work Experience

NordStar Consulting 2020 – Present

Founder, Principal, Doylestown, PA

Strengthened thought leader engagement and stakeholder experience management in large and medium biopharmaceutical companies. Transformed medical affairs and clinical trial operations.

MindScan 2017 – 2019

CEO, Doylestown, PA

Launched MindScan, a medical device company, to enable physicians and clinical R&D partners to substantially improve the accuracy and speed of diagnosing neuropsychiatric disorders.

Incorporated company and secured license and patent. Managed de novo regulatory submissions.

Completed primary market research, forecasts, and financial projections; led fundraising.

NordStar Consulting 2010 – 2017

Founder, Principal, Doylestown, PA

Strengthened thought leader engagement and stakeholder experience management in large and medium biopharmaceutical companies. Transformed a disjointed and activity focused approach within medical affairs and commercial to an integrated and strategy driven approach. Significantly improved internal teamwork and thought leader engagement. Evaluated clinical operations at a biopharmaceutical company through primary market research and made recommendations that significantly improved performance.

Immune Control 2007 - 2010

Chief Business Officer, West Conshohocken, PA

Led strategic and operational planning and execution of clinical studies (multiple myeloma; psoriasis). Substantially improved multiple myeloma clinical field operations in the U.S. and India. Ran novel drug development programs (asthma, pulmonary arterial hypertension). Coordinated business development and fundraising.

Merck 1990 – 2006

Vice President, Commercial Excellence, Whitehouse Station, NJ (2006)

Led global strategic initiative to improve product commercialization.

Managing Director, MSD Denmark, Glostrup, Denmark (2003 – 2005)

Provided general management leadership to organization of 150, including nine direct reports.

Led marketing, sales, and finance across seven therapeutic areas. Managed external affairs, human resources, regulatory, and clinical research.

Led turnaround of Danish operations and launched Icelandic subsidiary.

-Restructured organization in first two months. Promoted most capable people; cut unnecessary costs.

-Increased profit margin by 3.7% in 2003.

-Exceeded efficiency improvement targets by 26% in 2004 and by 66% in 2005.

-Increased net income by 26% and profit margin by 5% in 2005.

Grew Cozaar® to achieve the highest global market share (48% of angiotensin receptor blockers).

Business Unit Director, MSD Denmark, Glostrup, Denmark (2000 – 2003)

Led sales and marketing of pain and osteoporosis business unit. Managed staff of 20 and 6 direct reports. Also led the hospital and specialty products business unit for 8 months.

Achieved second highest market penetration in Europe of newly launched product.

Substantially increased business unit sales (81% CAGR).

Launched Fosamax Once Weekly® and transformed brand into high growth product (>50% CAGR) with strong market share gains (from <45% to 73%).

Senior Director, New Product Planning, Whitehouse Station, NJ (1996 – 1999)

Led global launch of Maxalt®, managed four direct reports, and led Global Marketing Team.

Developed and executed global marketing strategy and launched campaign focused on securing market leadership for Maxalt®.

Conceived and implemented thought leader advocacy process recognized as a company best practice.

Overcame thought leader concerns and competitor disinformation campaign linked to earlier failed phase two trial by developing and implementing a novel speaker training program.

Moved a 3rd or 4th entrant to 2nd highest global market share. Achieved global sales of $100M in 1999.

Director, Innovative Marketing, West Point, PA (1994 – 1995)

Raised $18M and recruited three direct reports to implement Vital Interests® a patient adherence program covering eight products with physician, retail pharmacy, and managed care customers.

Finalized and launched program to retail pharmacy, physician, and managed care customers.

Achieved a 340% ROI.

Customer Manager, Customer Market Planning, West Point, PA (1993)

Developed and implemented patient adherence pilots for Vital Interests® through physician, retail pharmacy, and managed care customers.

Market Research Analyst, West Point, PA (1992)

Managed market research projects. Received Management Award for breakthrough analysis of economic impact of patient non-adherence.

Sales Representative, Boston, MA (1990 - 1991)

Sold lipid lowering, anti-hypertensive, ophthalmic and pain products in physician offices and hospitals. Achieved highest percent to plan performance of Dolobid® in region (140%).

Education

Master in Business Administration (MBA), Harvard Business School, Boston, MA

Bachelor of Arts, History, University of Massachusetts, Amherst, MA

Contact this candidate